China Peptide Cancer Vaccine Market Size Analysis, Growth Trends & Forecast to 2034

China Peptide Cancer Vaccine Market Overview 

The China peptide cancer vaccine market is projected to expand from USD 0.55 billion in 2026 to USD 3.45 billion by 2034, registering a CAGR of 27.3% during 2026–2034. The China peptide cancer vaccine market is an emerging segment of cancer immunotherapy, driven by growing interest in precision oncology, personalized neoantigen vaccines, and advances in peptide synthesis and antigen-prediction technologies. Domestic developers, including Hangzhou Neoantigen Therapeutics Co., Ltd. and Minkai Biomedical Group Limited, are advancing peptide-based vaccine platforms, while research into shared-antigen vaccines and combination therapies is creating additional development opportunities. Demand is currently shaped primarily by clinical research, biotechnology investment, and collaborations between vaccine developers and oncology research centers rather than widespread commercial adoption. However, high clinical development costs, variability in patient immune responses, manufacturing complexity of individualized vaccines, and the need to demonstrate meaningful clinical efficacy remain significant barriers. Over the forecast period, market development will depend on clinical-trial outcomes, regulatory progress, scalable GMP manufacturing, and the ability to establish a commercially viable role for peptide vaccines alongside existing cancer treatments.

China Peptide Cancer Vaccine Market Growth Drivers

Growing demand for precision oncology and personalized cancer immunotherapy

The increase in the importance of precision oncology in recent years is driving the development of personalized peptide cancer vaccines in China because such drugs act by targeting tumor neoantigens, which have been identified using genome sequencing and bioinformatics analyses. In contrast to standardized medicine, personalized medicine may be used to create a vaccine to stimulate the targeted immune response against tumor-specific mutations. In their article published in Clinical Cancer Research on September 1, 2020, Fang et al. present the results of the clinical trials for a personalized neoantigen peptide vaccine known as iNeo-Vac-P01 produced by Hangzhou Neoantigen Therapeutics. The researchers tested 22 patients diagnosed with malignant tumors and obtained evidence of immune responses to the peptides (or peptide pools) in 80% of participants. Moreover, the disease control rate amounted to 71.4% in 21 of the examined patients. The findings suggest that combining genomics, personalized peptide vaccine design, and delivery in the clinic may be feasible in China. Nonetheless, the outcomes need further exploration and should not be considered conclusive yet.

Advances in AI-enabled neoantigen identification and peptide manufacturing

Advancements in the fields of artificial intelligence, bioinformatics, and peptide synthesis have been driving progress in the creation of personalized cancer vaccines in China by enabling the more efficient detection of tumor-specific neoantigens and facilitating the development process of such vaccines. The use of algorithms based on artificial intelligence allows developers to identify mutations in tumors, predict the processing of antigens, and select the most promising peptide sequences that would initiate an immune response in a particular individual. Thus, such capabilities can help developers overcome challenges associated with personalized vaccine development. At the same time, the progress in peptide synthesis, separation, purification, formulation, and quality control enables moving beyond computer models and entering the clinical stage. According to the Journal for ImmunoTherapy of Cancer published on November 7, 2025, one Chinese clinical trial involving the iNeo-Vac-P01 neoantigen peptide vaccine demonstrated the development of the neoantigen pipeline that includes tumor sequencing, peptide selection for each patient individually, and subsequent delivery in patients with esophageal cancer. Additionally, the company disclosures from Minkai Biomedical show that the company has been able to integrate high-throughput sequencing and AI neoantigen predictions with peptide synthesis and purification at GMP facilities. All these developments represent examples of how computational screening and peptide production within the country could benefit the development of vaccines. However, its commercial potential depends on successful validation and manufacturing.

China Peptide Cancer Vaccine Market Restraints

High clinical-development complexity and uncertain therapeutic efficacy

High clinical-development complexity and uncertain therapeutic efficacy restrain the growth of the China Peptide Cancer Vaccine Market, as developing effective vaccines requires the identification of tumor-specific antigens, precise peptide selection, and validation of immune responses across different cancer types and patient populations. The highly individualized nature of personalized peptide vaccines adds complexity to clinical trial design, manufacturing consistency, patient selection, and regulatory approval. In China, developers must establish clear evidence of safety, durable immune responses, and meaningful clinical benefits before these vaccines can achieve broader clinical adoption. Variations in tumor mutations, immune-system responses, and disease progression can also lead to inconsistent treatment outcomes, increasing the time and financial investment required for clinical development. These challenges raise development costs and commercialization risks, potentially delaying product launches, limiting investor confidence, and slowing the adoption of peptide cancer vaccines in the Chinese oncology market.

China Peptide Cancer Vaccine Market Opportunities

Combination therapies and scalable shared-antigen peptide vaccines.

Peptide cancer vaccine market through empowering developers to enhance anti-tumor immunity and broaden treatment scope from personalized vaccines to alternatives for treatment. Using peptide vaccines alongside other immuno-stimulatory treatments like immune checkpoint inhibitors, e.g., PD-1 or PD-L1 inhibitors, may increase T-cell activity due to the vaccine treatment and overcome tumor escape pathways from the immune system. On the other hand, shared-antigen vaccines work with tumor-related antigens present in several patients, making manufacturing processes more standard and decreasing production cost per unit, thus broadening patient access compared to neoantigen vaccines. Chinese developers may benefit greatly from these technologies as they provide scalable manufacturing options, but only after demonstrating their benefits in controlled trials. According to a study in Nature Medicine on March 27, 2024, an interim report of phase one results of a neoantigen vaccine based on 20 shared cancer mutations used together with checkpoint inhibitors Nivo and Yervoy was presented. While the treatment did not have serious side effects, the trial found no objective responses in the first 19 patients who participated. Phase II randomized clinical trials of personalized neoantigen vaccines used in conjunction with radiotherapy to treat advanced cancer were registered in China in November 2023. This shows that there is interest among researchers in combination-based treatment systems. This represents an opportunity for vaccine platform development by Chinese vaccine manufacturers for shared antigens using combination therapies that would benefit a greater range of people.

China Peptide Cancer Vaccine Market Scope

China Peptide Cancer Vaccine Market Report Segmentation Analysis

Personalized Peptide Vaccines Segment Is Expected to Dominate the China Peptide Cancer Vaccine Market During the Forecast Period

The personalized peptide vaccines segment is likely to capture the largest share of the China peptide cancer vaccine market over the forecast period due to the increased emphasis on personalized oncology and the use of immunotherapies that target the specific mutation of the tumor in individual patients. Personalized peptide vaccines are generated based on specific peptides generated from tumor sequencing and bioinformatics analysis, helping the immune system identify and kill the cancer cells. In China, there are opportunities in the field of tumor sequencing, AI-based neoantigen predictions, and peptide synthesis. China’s expanding oncology research ecosystem and increased clinical trials of individualized therapies have also been boosting the popularity of this segment. Despite the high cost of manufacturing, complex production processes depending on each patient, and the lack of strong efficacy of personalized peptide vaccines, continuous technological advancements can help this segment grow over the forecast period.  

Melanoma Segment Is Expected to Dominate the China Peptide Cancer Vaccine Market During the Forecast Period

The China melanoma peptide cancer vaccine market segment will dominate in the coming years, as per the forecast, because of the existing use of tumor-specific antigens in the immunization process of melanoma and the development of peptide cancer vaccines directed against melanoma-specific antigens and tumor-specific neoantigens. There have been many melanomas used in cancer vaccine research since their high mutation rate results in the formation of neoantigens. The neoantigens formed are recognized by the immune system and therefore are a good indication to develop a personalized peptide vaccine. Opportunities for researching peptide vaccines in China include research into the identification of the neoantigen, tumour sequencing, and combination immunotherapies. Using this vaccine together with immune checkpoint inhibitors can also help to increase the antitumor immunity. Nevertheless, there is still a need to find out how clinical trials will turn out before considering the potential for this segment to grow.

Hospitals Segment Is Expected to Dominate the China Peptide Cancer Vaccine Market During the Forecast Period

The hospitals sub-segment is anticipated to dominate the China peptide cancer vaccine market during the forecast period owing to the availability of oncologists, diagnostics, research infrastructure, and multidisciplinary cancer treatment facilities in hospitals. Peptide cancer vaccines, especially personalized neoantigen vaccines, require the analysis of tumor tissues, genomic sequencing, patient-specific vaccine creation, and clinical follow-ups, making hospitals one of the important sites for investigating the same. The combination of immunotherapy with standard therapies such as chemotherapy and radiation therapy will further fuel the demand for peptide cancer vaccines in hospitals. For example, in a study published in Cancer Research on July 1, 2019, scientists at Sir Run Run Shaw Hospital, Zhejiang University School of Medicine conducted a Phase I clinical trial of personalized neoantigen peptide vaccine iNeo-Vac-P01 in patients suffering from advanced malignancies. This indicates the contribution of Chinese medical institutions in the development of personalized peptide vaccines. With the increasing clinical trials and developing evidence on the safety and efficacy of the product, hospitals will continue to be the major setting for clinical trials and early adoption of peptide cancer vaccines in China.

The following segments are part of an in-depth analysis of the China Peptide Cancer Vaccine Market:

China Peptide Cancer Vaccine Market Competition Landscape Analysis

The China peptide cancer vaccine market is mainly driven by Chinese biotechnology firms, research institutes, and hospitals involved in creating personalized neoantigen and shared antigen peptide vaccines. The competition in the market is mainly research and development-based, whereby the differentiation is mainly in terms of neoantigen identification, peptide synthesis capability, clinical trials, and partnerships with hospitals. The developers of such vaccines have challenges in terms of high development costs, personalized manufacturing, regulatory issues, and uncertain efficacy. This means that those with clinical success and manufacturing ability can compete better.

China Peptide Cancer Vaccine Market Recent Developments News:

• In August 2026, Leman China reported that Chinese authorities had approved 19 new foot-and-mouth disease (FMD) products targeting the SAT1 serotype, developed by nine companies. The approved portfolio included synthetic peptide vaccines alongside inactivated and virus-like particle vaccines, reflecting continued innovation in peptide-based vaccine technology. However, these products target animal health and should not be considered direct developments in the human peptide cancer vaccine market.

• In April 2026, ZMUni Compliance Centre reported that two cyclic peptide ingredients had completed notifications under China’s new cosmetic ingredient framework. One was filed by Proya, while Zhejiang Peptites Biotech filed Cyclo sh-Pentapeptide-46 SP. Although this highlights domestic peptide innovation and regulatory activity, the development relates to cosmetics rather than cancer vaccines  

The China Peptide Cancer Vaccine Market is dominated by a few large companies, such as

• Hangzhou Neoantigen Therapeutics Co., Ltd.

• Minkai Biomedical Group Limited

• Harbin Jixianglong Biotech Co., Ltd.

• SELLAS Life Sciences Group, Inc.

• MimiVax, Inc.

• PDS Biotechnology Corporation

• Greenwich LifeSciences, Inc.

• Elicio Therapeutics, Inc.

• OSE Immunotherapeutics SA

• OncoTherapy Science, Inc.

• Evaxion A/S

• Enterome SA

• BrightPath Biotherapeutics Co., Ltd.

• Imugene Limited

• Marker Therapeutics, Inc.

• Other Prominent Players